{"id":"ccrt-with-weekly-docetaxel-cisplatin","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel binds to tubulin, preventing microtubule polymerization, and cisplatin forms platinum-DNA adducts, inhibiting DNA replication and transcription.","oneSentence":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:58.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT02923258","phase":"PHASE2, PHASE3","title":"Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2018-04-21","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":224},{"nctId":"NCT02512315","phase":"PHASE3","title":"A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Nasopharyngeal Carcinoma","enrollment":192},{"nctId":"NCT01126008","phase":"PHASE2","title":"Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-11-16","conditions":"Head and Neck Cancer","enrollment":44},{"nctId":"NCT02640898","phase":"NA","title":"Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-12","conditions":"Gastric Cancer","enrollment":500},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT03161548","phase":"PHASE2","title":"A Study of Tongue Conservation Surgery for Oral Tongue Cancer","status":"TERMINATED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2011-07-18","conditions":"Tongue Cancer, Chemotherapy Effect, Surgery","enrollment":23},{"nctId":"NCT02703961","phase":"PHASE3","title":"Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2016-02","conditions":"Cervical Cancer","enrollment":598},{"nctId":"NCT02120118","phase":"PHASE2","title":"Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors","status":"WITHDRAWN","sponsor":"Shin Kong Wu Ho-Su Memorial Hospital","startDate":"2014-02","conditions":"Solid Tumors","enrollment":""},{"nctId":"NCT00326378","phase":"PHASE3","title":"Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2005-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":434},{"nctId":"NCT01999933","phase":"PHASE2, PHASE3","title":"Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer","status":"UNKNOWN","sponsor":"Mei Shi","startDate":"2013-11","conditions":"Cervical Cancer, Toxicity Due to Radiotherapy","enrollment":600},{"nctId":"NCT01516996","phase":"PHASE2","title":"Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer","status":"UNKNOWN","sponsor":"The Second People's Hospital of Sichuan","startDate":"2012-03","conditions":"Oropharyngeal Cancer, Hypopharyngeal Cancer","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CCRT with weekly docetaxel & cisplatin","genericName":"CCRT with weekly docetaxel & cisplatin","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Used for Non-small cell lung cancer, Prostate cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}